Fabry Disease Market Pipeline Review in H2 2016 Report

USA - English

• India - English

PUNE, India, September 29, 2016 /PRNewswire/ --

ReportsnReports.com adds "Fabry Disease - Pipeline Review, H2 2016" market research report with comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects.

Complete report on H2 2016 pipeline review of Fabry Disease with 26 market data tables and 12 figures, spread across 81 pages is available at http://www.reportsnreports.com/reports/697559-fabry-disease-pipeline-review-h2-2016.html.

Fabry Disease pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. Global Markets Direct's latest report Fabry Disease - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called globotriaosylceramide) in blood vessel walls throughout the body. Symptoms include pain, diarrhea, nausea, kidney problems, tinnitus, irregular heartbeat, and leaky heart valves. Treatment includes enzyme replacement therapy (ERT). The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 2, 2 and 6 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects. Driven by data built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Companies discussed in this Fabry Disease Pipeline Review, H2 2016 report include Actelion Ltd, Alexion Pharmaceuticals Inc, Amicus Therapeutics, Inc., Genzyme Corporation, Greenovation Biotech GmbH, ISU ABXIS Co.,Ltd., JCR Pharmaceuticals Co., Ltd., Neuraltus Pharmaceuticals, Inc., Pharming Group N.V., Protalix BioTherapeutics, Inc., Sangamo BioSciences, Inc. and Shire Plc. Drug Profiles mentioned in this research report are agalsidase alfa, agalsidase beta biosimilar, AVR-02, Enzyme Replacement Therapy + migalastat hydrochloride Biobetter, ibiglustat, lucerastat, migalastat hydrochloride, MOSS-AGAL, NP-003, PRX-102, Recombinant Alpha-Galactosidase A Replacement for Fabry Disease, Recombinant Enzymes for Pompe, Fabry and Hunter Diseases and SBLSD-4.

Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=697559 .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Another newly published market research report titled on Batten Disease - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Batten Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Batten Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Abeona Therapeutics, Inc., BioMarin Pharmaceutical Inc., CereSpir Incorporated, Evotec AG, Ionis Pharmaceuticals, Inc., Mitochon Pharmaceuticals, Inc., RegenxBio Inc., Retrotope, Inc and Spark Therapeutics, Inc. Batten Disease Pipeline market research report of 72 pages is available at http://www.reportsnreports.com/reports/697557-batten-disease-pipeline-review-h2-2016.html .

Explore more reports on Pharmaceuticals.

About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
2nd floor, Metropole, Next to Inox Theatre, Bund Garden Road,
Pune-411001
Maharashtra, India
Tel: +1-888-391-5441
[email protected]

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports